$RGLS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Regulus Therapeutics Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Regulus Therapeutics Inc.. Get notifications about new insider transactions in Regulus Therapeutics Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 02 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President and CEO | Option Exercise | M | 0.38 | 2,300 | 874 | 452,997 | |
| Oct 02 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President and CEO | Sell | S | 7.02 | 2,300 | 16,137 | 2,466 | 4.8 K to 2.5 K (-48.26 %) |
| Oct 02 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President and CEO | Buy | M | 0.38 | 2,300 | 874 | 4,766 | 2.5 K to 4.8 K (+93.27 %) |
| Sep 26 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.04 | 2,500 | 17,598 | 6,042,250 | 6 M to 6 M (-0.04 %) |
| Sep 26 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.12 | 2,500 | 17,790 | 6,044,750 | 6 M to 6 M (-0.04 %) |
| Sep 26 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.19 | 3,750 | 26,978 | 6,047,250 | 6.1 M to 6 M (-0.06 %) |
| Sep 26 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.04 | 2,500 | 17,598 | 6,941,250 | 6.9 M to 6.9 M (-0.04 %) |
| Sep 26 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.12 | 2,500 | 17,790 | 6,943,750 | 6.9 M to 6.9 M (-0.04 %) |
| Sep 26 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.19 | 3,750 | 26,978 | 6,946,250 | 7 M to 6.9 M (-0.05 %) |
| Sep 19 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.22 | 4,100 | 29,587 | 6,950,000 | 7 M to 7 M (-0.06 %) |
| Sep 19 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.40 | 1,500 | 11,098 | 6,954,100 | 7 M to 7 M (-0.02 %) |
| Sep 19 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.43 | 2,100 | 15,610 | 6,955,600 | 7 M to 7 M (-0.03 %) |
| Sep 19 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.22 | 4,100 | 29,587 | 6,051,000 | 6.1 M to 6.1 M (-0.07 %) |
| Sep 19 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.40 | 1,500 | 11,098 | 6,055,100 | 6.1 M to 6.1 M (-0.02 %) |
| Sep 19 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.43 | 2,100 | 15,610 | 6,056,600 | 6.1 M to 6.1 M (-0.03 %) |
| Sep 15 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 2,200 | 3,828 | 119,800 | |
| Sep 15 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 2,000 | 3,480 | 122,000 | |
| Sep 15 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 8.01 | 2,200 | 17,617 | 80,000 | 82.2 K to 80 K (-2.68 %) |
| Sep 15 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 2,200 | 3,828 | 82,200 | 80 K to 82.2 K (+2.75 %) |
| Sep 15 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 8.01 | 2,000 | 16,010 | 80,000 | 82 K to 80 K (-2.44 %) |
| Sep 15 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 2,000 | 3,480 | 82,000 | 80 K to 82 K (+2.50 %) |
| Sep 12 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.96 | 3,500 | 27,861 | 6,957,700 | 7 M to 7 M (-0.05 %) |
| Sep 12 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.83 | 3,400 | 26,636 | 6,961,200 | 7 M to 7 M (-0.05 %) |
| Sep 12 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.70 | 2,000 | 15,399 | 6,964,600 | 7 M to 7 M (-0.03 %) |
| Sep 12 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.96 | 3,500 | 27,861 | 6,058,700 | 6.1 M to 6.1 M (-0.06 %) |
| Sep 12 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.83 | 3,400 | 26,636 | 6,062,200 | 6.1 M to 6.1 M (-0.06 %) |
| Sep 12 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.70 | 2,000 | 15,399 | 6,065,600 | 6.1 M to 6.1 M (-0.03 %) |
| Sep 05 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.07 | 2,400 | 16,974 | 6,067,600 | 6.1 M to 6.1 M (-0.04 %) |
| Sep 05 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.11 | 6,000 | 42,656 | 6,070,000 | 6.1 M to 6.1 M (-0.10 %) |
| Sep 05 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.95 | 1,650 | 11,471 | 6,076,000 | 6.1 M to 6.1 M (-0.03 %) |
| Sep 05 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.07 | 2,400 | 16,974 | 6,966,600 | 7 M to 7 M (-0.03 %) |
| Sep 05 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.11 | 6,000 | 42,656 | 6,969,000 | 7 M to 7 M (-0.09 %) |
| Sep 05 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.95 | 1,650 | 11,471 | 6,975,000 | 7 M to 7 M (-0.02 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.84 | 1,500 | 10,254 | 6,976,650 | 7 M to 7 M (-0.02 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.96 | 2,000 | 13,921 | 6,978,150 | 7 M to 7 M (-0.03 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.21 | 1,500 | 10,821 | 6,980,150 | 7 M to 7 M (-0.02 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.84 | 1,500 | 10,254 | 6,077,650 | 6.1 M to 6.1 M (-0.02 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.96 | 2,000 | 13,921 | 6,079,150 | 6.1 M to 6.1 M (-0.03 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.21 | 1,500 | 10,821 | 6,081,150 | 6.1 M to 6.1 M (-0.02 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 3,505 | 1,332 | 455,297 | |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 7.06 | 3,505 | 24,754 | 0 | 3.5 K to 0 (-100.00 %) |
| Aug 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 3,505 | 1,332 | 3,505 | 0 to 3.5 K |
| Aug 22 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.75 | 5,250 | 35,443 | 6,082,650 | 6.1 M to 6.1 M (-0.09 %) |
| Aug 22 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.89 | 2,500 | 17,222 | 6,087,900 | 6.1 M to 6.1 M (-0.04 %) |
| Aug 22 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.14 | 3,000 | 21,424 | 6,090,400 | 6.1 M to 6.1 M (-0.05 %) |
| Aug 22 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.75 | 5,250 | 35,443 | 6,981,650 | 7 M to 7 M (-0.08 %) |
| Aug 22 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.89 | 2,500 | 17,222 | 6,986,900 | 7 M to 7 M (-0.04 %) |
| Aug 22 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.14 | 3,000 | 21,424 | 6,989,400 | 7 M to 7 M (-0.04 %) |
| Aug 15 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.98 | 1,450 | 10,115 | 6,093,400 | 6.1 M to 6.1 M (-0.02 %) |
| Aug 15 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.04 | 1,750 | 12,324 | 6,094,850 | 6.1 M to 6.1 M (-0.03 %) |
| Aug 15 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.02 | 2,250 | 15,788 | 6,096,600 | 6.1 M to 6.1 M (-0.04 %) |
| Aug 15 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.98 | 1,450 | 10,115 | 6,992,400 | 7 M to 7 M (-0.02 %) |
| Aug 15 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.04 | 1,750 | 12,324 | 6,993,850 | 7 M to 7 M (-0.03 %) |
| Aug 15 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.02 | 2,250 | 15,788 | 6,995,600 | 7 M to 7 M (-0.03 %) |
| Aug 08 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.80 | 1,850 | 12,583 | 6,997,850 | 7 M to 7 M (-0.03 %) |
| Aug 08 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.66 | 2,600 | 17,322 | 6,999,700 | 7 M to 7 M (-0.04 %) |
| Aug 08 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.08 | 3,150 | 22,300 | 7,002,300 | 7 M to 7 M (-0.04 %) |
| Aug 08 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.80 | 1,850 | 12,583 | 6,098,850 | 6.1 M to 6.1 M (-0.03 %) |
| Aug 08 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.66 | 2,600 | 17,322 | 6,100,700 | 6.1 M to 6.1 M (-0.04 %) |
| Aug 08 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.08 | 3,150 | 22,300 | 6,103,300 | 6.1 M to 6.1 M (-0.05 %) |
| Aug 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 3,505 | 1,332 | 458,802 | |
| Aug 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 7.06 | 3,505 | 24,739 | 0 | 3.5 K to 0 (-100.00 %) |
| Aug 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 3,505 | 1,332 | 3,505 | 0 to 3.5 K |
| Aug 01 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.21 | 2,600 | 16,153 | 6,106,450 | 6.1 M to 6.1 M (-0.04 %) |
| Aug 01 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.42 | 1,750 | 11,235 | 6,109,050 | 6.1 M to 6.1 M (-0.03 %) |
| Aug 01 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.60 | 1,000 | 6,602 | 6,110,800 | 6.1 M to 6.1 M (-0.02 %) |
| Aug 01 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.21 | 2,600 | 16,153 | 7,005,450 | 7 M to 7 M (-0.04 %) |
| Aug 01 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.42 | 1,750 | 11,235 | 7,008,050 | 7 M to 7 M (-0.02 %) |
| Aug 01 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.60 | 1,000 | 6,602 | 7,009,800 | 7 M to 7 M (-0.01 %) |
| Jul 25 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.55 | 1,700 | 11,137 | 7,010,800 | 7 M to 7 M (-0.02 %) |
| Jul 25 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.81 | 1,850 | 12,598 | 7,012,500 | 7 M to 7 M (-0.03 %) |
| Jul 25 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.88 | 1,700 | 11,702 | 7,014,350 | 7 M to 7 M (-0.02 %) |
| Jul 25 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.55 | 1,700 | 11,137 | 6,111,800 | 6.1 M to 6.1 M (-0.03 %) |
| Jul 25 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.81 | 1,850 | 12,598 | 6,113,500 | 6.1 M to 6.1 M (-0.03 %) |
| Jul 25 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.88 | 1,700 | 11,702 | 6,115,350 | 6.1 M to 6.1 M (-0.03 %) |
| Jul 18 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.80 | 5,000 | 34,001 | 7,016,050 | 7 M to 7 M (-0.07 %) |
| Jul 18 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.58 | 5,000 | 32,906 | 7,021,050 | 7 M to 7 M (-0.07 %) |
| Jul 18 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.59 | 3,500 | 23,058 | 7,026,050 | 7 M to 7 M (-0.05 %) |
| Jul 18 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.80 | 5,000 | 34,001 | 6,117,050 | 6.1 M to 6.1 M (-0.08 %) |
| Jul 18 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.58 | 5,000 | 32,906 | 6,122,050 | 6.1 M to 6.1 M (-0.08 %) |
| Jul 18 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.59 | 3,500 | 23,058 | 6,127,050 | 6.1 M to 6.1 M (-0.06 %) |
| Jul 11 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.48 | 1,750 | 11,339 | 7,029,550 | 7 M to 7 M (-0.02 %) |
| Jul 11 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 6.69 | 4,500 | 30,109 | 7,031,300 | 7 M to 7 M (-0.06 %) |
| Jul 11 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | Director | Sell | S | 7.08 | 1,800 | 12,748 | 7,035,800 | 7 M to 7 M (-0.03 %) |
| Jul 11 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.48 | 1,750 | 11,339 | 6,130,550 | 6.1 M to 6.1 M (-0.03 %) |
| Jul 11 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 6.69 | 4,500 | 30,109 | 6,132,300 | 6.1 M to 6.1 M (-0.07 %) |
| Jul 11 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.08 | 1,800 | 12,748 | 6,136,800 | 6.1 M to 6.1 M (-0.03 %) |
| Jul 07 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 8.07 | 1,200 | 9,678 | 6,138,600 | 6.1 M to 6.1 M (-0.02 %) |
| Jul 07 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 8.07 | 3,100 | 25,011 | 6,139,800 | 6.1 M to 6.1 M (-0.05 %) |
| Jul 07 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.07 | 1,200 | 9,678 | 7,037,600 | 7 M to 7 M (-0.02 %) |
| Jul 07 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.07 | 3,100 | 25,011 | 7,038,800 | 7 M to 7 M (-0.04 %) |
| Jul 02 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 2,500 | 4,350 | 124,000 | |
| Jul 02 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 8.10 | 2,500 | 20,260 | 80,000 | 82.5 K to 80 K (-3.03 %) |
| Jul 02 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 2,500 | 4,350 | 82,500 | 80 K to 82.5 K (+3.13 %) |
| Jul 02 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 3,505 | 1,332 | 462,307 | |
| Jul 02 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 8.11 | 3,505 | 28,426 | 0 | 3.5 K to 0 (-100.00 %) |
| Jul 02 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 3,505 | 1,332 | 3,505 | 0 to 3.5 K |
| Jun 27 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | 10% Owner | Sell | S | 7.91 | 3,150 | 24,931 | 7,041,900 | 7 M to 7 M (-0.04 %) |
| Jun 27 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | 10% Owner | Sell | S | 7.89 | 1,700 | 13,408 | 7,045,050 | 7 M to 7 M (-0.02 %) |
| Jun 27 2014 | RGLS | Regulus Therapeuti ... | ISIS PHARMACEUTICALS INC | 10% Owner | Sell | S | 7.84 | 2,750 | 21,566 | 7,046,750 | 7 M to 7 M (-0.04 %) |
| Jun 27 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.91 | 3,150 | 24,931 | 6,142,900 | 6.1 M to 6.1 M (-0.05 %) |
| Jun 27 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.89 | 1,700 | 13,408 | 6,146,050 | 6.1 M to 6.1 M (-0.03 %) |
| Jun 27 2014 | RGLS | Regulus Therapeuti ... | ALNYLAM PHARMACEUTICALS, INC. | 10% Owner | Sell | S | 7.84 | 2,750 | 21,566 | 6,147,750 | 6.2 M to 6.1 M (-0.04 %) |
| Jun 18 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 5,000 | 8,700 | 126,500 | |
| Jun 18 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 8.05 | 5,000 | 40,227 | 80,000 | 85 K to 80 K (-5.88 %) |
| Jun 18 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 5,000 | 8,700 | 85,000 | 80 K to 85 K (+6.25 %) |
| Jun 18 2014 | RGLS | Regulus Therapeuti ... | GRINT PAUL C | Chief Medical Offic ... | Option Exercise | A | 7.58 | 250,000 | 1,895,000 | 250,000 | |
| Jun 09 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 3,505 | 1,332 | 465,812 | |
| Jun 09 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 7.14 | 3,505 | 25,017 | 0 | 3.5 K to 0 (-100.00 %) |
| Jun 09 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 3,505 | 1,332 | 3,505 | 0 to 3.5 K |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 887 | 337 | 469,317 | |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 875 | 333 | 470,204 | |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 1,743 | 662 | 471,079 | |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 7.00 | 887 | 6,209 | 0 | 887 to 0 (-100.00 %) |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 887 | 337 | 887 | 0 to 887 |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 7.00 | 875 | 6,126 | 0 | 875 to 0 (-100.00 %) |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 875 | 333 | 875 | 0 to 875 |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 7.00 | 1,743 | 12,203 | 0 | 1.7 K to 0 (-100.00 %) |
| May 29 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 1,743 | 662 | 1,743 | 0 to 1.7 K |
| May 22 2014 | RGLS | Regulus Therapeuti ... | WILLIAMS DOUGLAS E | Director | Option Exercise | A | 6.22 | 17,500 | 108,850 | 17,500 | |
| May 22 2014 | RGLS | Regulus Therapeuti ... | RASTETTER WILLIAM H | Director | Option Exercise | A | 6.22 | 17,500 | 108,850 | 17,500 | |
| May 22 2014 | RGLS | Regulus Therapeuti ... | FOLETTA MARK G | Director | Option Exercise | A | 6.22 | 17,500 | 108,850 | 17,500 | |
| May 22 2014 | RGLS | Regulus Therapeuti ... | PAPADOPOULOS STELIOS | Director | Option Exercise | A | 6.22 | 17,500 | 108,850 | 17,500 | |
| May 22 2014 | RGLS | Regulus Therapeuti ... | BALTIMORE DAVID | Director | Option Exercise | A | 6.22 | 5,000 | 31,100 | 5,000 | |
| May 22 2014 | RGLS | Regulus Therapeuti ... | BALTIMORE DAVID | Director | Option Exercise | A | 6.22 | 17,500 | 108,850 | 17,500 | |
| May 22 2014 | RGLS | Regulus Therapeuti ... | CARTER BRUCE L A | Director | Option Exercise | A | 6.22 | 17,500 | 108,850 | 17,500 | |
| Apr 10 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 2,500 | 4,350 | 42,591 | |
| Apr 10 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 8.11 | 2,500 | 20,271 | 80,000 | 82.5 K to 80 K (-3.03 %) |
| Apr 10 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 2,500 | 4,350 | 82,500 | 80 K to 82.5 K (+3.13 %) |
| Apr 09 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 3,505 | 1,332 | 472,822 | |
| Apr 09 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 7.60 | 3,505 | 26,623 | 80,216 | 83.7 K to 80.2 K (-4.19 %) |
| Apr 09 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 3,505 | 1,332 | 83,721 | 80.2 K to 83.7 K (+4.37 %) |
| Mar 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 3,505 | 1,332 | 476,327 | |
| Mar 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 11.35 | 3,505 | 39,778 | 80,216 | 83.7 K to 80.2 K (-4.19 %) |
| Mar 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 3,505 | 1,332 | 83,721 | 80.2 K to 83.7 K (+4.37 %) |
| Mar 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 2,500 | 4,350 | 45,091 | |
| Mar 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 11.37 | 2,500 | 28,429 | 80,000 | 82.5 K to 80 K (-3.03 %) |
| Mar 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 2,500 | 4,350 | 82,500 | 80 K to 82.5 K (+3.13 %) |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Option Exercise | M | 0.38 | 3,505 | 1,332 | 479,832 | |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Sell | S | 8.40 | 3,505 | 29,437 | 80,216 | 83.7 K to 80.2 K (-4.19 %) |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | XANTHOPOULOS KLEANTHIS G | President & CEO | Buy | M | 0.38 | 3,505 | 1,332 | 83,721 | 80.2 K to 83.7 K (+4.37 %) |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 45,000 | 78,300 | 2,591 | |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 1.74 | 2,500 | 4,350 | 47,591 | |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 45,000 | 78,300 | 80,000 | 35 K to 80 K (+128.57 %) |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 8.38 | 17,500 | 146,706 | 35,000 | 52.5 K to 35 K (-33.33 %) |
| Feb 07 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 1.74 | 2,500 | 4,350 | 52,500 | 50 K to 52.5 K (+5.00 %) |
| Feb 05 2014 | RGLS | Regulus Therapeuti ... | Sanofi | 10% Owner | Buy | P | 7.67 | 1,303,780 | 9,999,993 | 5,053,779 | 3.7 M to 5.1 M (+34.77 %) |
| Jan 23 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Option Exercise | M | 2.66 | 4,421 | 11,760 | 701 | |
| Jan 23 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Sell | S | 8.09 | 4,421 | 35,764 | 50,000 | 54.4 K to 50 K (-8.12 %) |
| Jan 23 2014 | RGLS | Regulus Therapeuti ... | Gibson Neil W | Chief Scientific Of ... | Buy | M | 2.66 | 4,421 | 11,760 | 54,421 | 50 K to 54.4 K (+8.84 %) |